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SUMMARY 
 
The formation of various types of kidney stones is strongly influenced by urinary pH. 
An alkaline pH favours the crystallization of calcium and phosphate containing 
stones, whereas and acidic urine pH promotes uric acid or cystine stones. The 
activity of many transport processes involved in calcium, citrate, and phosphate 
handling are sensitive to changes in systemic or local pH as shown for several 
phosphate transporters, the citrate transporter NaDC1, or the TRPV5 calcium 
channel. Defects in urinary acidification (excretion of inappropriately alkaline or acidic 
urines, respectively) contribute to kidney stone disease. The low excretion of 
ammonium in patients with metabolic syndrome has been linked to more acidic urine 
and a higher incidence of uric acid stones. In this state, insulin resistance may reduce 
ammonium excretion by the proximal tubule. On the other hand, defensive 
mechanisms may protect from kidney stone formation in conditions such as 
hypercalciuria where high luminal calcium concentrations stimulate urinary 
acidification and reduce urinary concentration via a Calcium-sensing receptor 
resulting in the excretion of acidic and diluted urine. This review will discuss a few 
aspects that relate to the capacity of the kidney to regulate pH and its impact on the 
excretion of solutes that participate in the formation or prevention of stones.  
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INTRODUCTION 
 
 Kidney stones are a common health problem in industrialized countries 
affecting between 2-5 % of the population during lifetime at least once. A 
considerable percentage of patients, however, experiences recurrent kidney stones 
with pain, urinary tract infections, and possibly leading to loss of functional renal 
parenchyma which may ultimately cause even renal insufficiency. Many factors 
predispose or contribute to the development of kidney stones including genetic 
variants or mutations, diet, environmental factors, and behaviour (1-3).  
 Genetic studies in humans and animal models have helped to dissect some 
pathways that increase the risk to develop kidney stones. Mutations in several 
enzymes, transporters, receptors or channels have been identified in patients with 
rare mendelian forms of kidney stones. Many of these mutations cause either an 
increased excretion of substances that can form crystals or stones, alter the 
composition of the urine leading to conditions that favour crystal formation, or both.  
Examples include mutations in the CLC-5 chloride/proton exchanger in Dent's 
disease, in the chloride/bicarbonate exchanger AE1 (SLC4A1), in the calcium-
sensing receptor CaSR, in Bartter's syndrome (mutations in ROMK, NKCC2, ClC-Kb, 
or Barttin), claudin 16, or the two subunits of the cystine transporter b0,+AT-rbAT in 
cystinuria (SLC7A9-SLC3A2) (1,3-4). 
  
 Alterations in urinary pH can be caused by genetic variants or mutations in 
transport pathways, by life style habits such as specific diets, or metabolic diseases. 
Inappropriately acidic or alkaline urine affects the solubility of various metabolites and 
salts. Alkaline urine reduces solubility of calcium phosphate products whereas acidic 
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urine pH promotes formation of uric acid or cystine containing stones (1-3). 
Moreover, changes in systemic pH homeostasis as seen in forms of chronic 
metabolic acidosis alter urine concentrations of substances that contribute to crystal 
formation (e.g. calcium, phosphate) as well as of substances that may prevent stone 
formation (e.g. citrate or magnesium). 
 
 Here, we will review briefly mechanisms that contribute to stone formation and 
relate to either systemic acid-base homeostasis or urinary acidification. We will not 
be able to discuss in detail a large body of literature on other forms and causes of 
nephrolithiasis, or its treatment. 
 
 
Local or systemic acidosis alters renal excretion of solutes involved in kidney 
stone formation 
 
The impact of systemic acid-base homeostasis and/or urinary acidification on 
the urinary excretion of stone-forming minerals and metabolites has been elucidated 
on the molecular levels for several substrates. Urinary phosphate excretion increases 
during metabolic acidosis where urinary phosphate plays an important role as part of 
the titratable acidity (5-7). The increase in urinary phosphaturia is paralleled by 
stimulated expression of the intestinal phosphate transporter NaPi-IIb that might 
contribute to the compensation of renal phosphate losses (8). Moreover, bone 
releases massive amounts of phosphate which in chronic acidosis favors bone 
mineral losses (9). Thus, increased intestinal phosphate absorption as well as 
release of phosphate from bone may contribute to renal phosphate excretion. 
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Moreover, systemic acidosis and local urinary acidification most likely play an 
important role by directly affecting phosphate reabsorption in the proximal tubule. It 
has been discussed whether systemic acidosis increases phosphaturia by reducing 
the expression of the NaPi-IIa phosphate cotransporter. Ambühl et al. demonstrated 
reduced mRNA and protein levels in rat kidney (6), whereas we (10) and Villa-
Bellosta did not find changes in expression in mouse and rat kidney (11). Moreover, 
NaPi-IIc and Pit2, two other proximal phosphate transporters, even increase their 
expression, possibly to compensate for renal phosphate losses. Local pH, however, 
has a strong impact on the function of brush border membrane phosphate 
transporters. Acidic pH decreases activity of the two main transporter, NaPi-IIa and 
NaPi-IIc, whereas Pit2 is stimulated (11), {Amstutz, 1985 #86}{Ravera, 2007 #386}. 
 
During acidosis, the urinary excretion of calcium and magnesium is also 
increased (12). Systemic acidosis downregulates the expression and activity of the 
TRPV5 calcium channel, expressed in the late distal convoluted tubule and 
connecting tubule (13). In contrast, it increases expression of the calcium-binding 
protein calbindin 28k (14). Similar to proximal tubular phosphate transporters, local 
pH also directly affects the function and recycling of the TRPV5 channel (12,15). 
Thus, local and systemic acidosis increases urinary excretion of calcium and 
phosphate and thereby increases the risk for crystallization and stone formation.  
 
Moreover, the excretion of citrate, an important anti-lithogenic metabolite, is 
decreased during acidosis. Citrate inhibits stone formation by complexing with 
calcium in the urine, reducing spontaneous nucleation, and thereby preventing 
growth and agglomeration of crystals (16). Urinary citrate excretion is determined by 
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the amount of citrate filtered in the glomerulum and the subsequent reabsorption at 
the level of the proximal tubule by the sodium-dependent citrate cotransporter NaDC-
1 expressed in the brush border membrane. Expression and activity of NaDC-1 is 
increased during metabolic acidosis or potassium depletion thereby lowering urinary 
citrate levels (17-18). 
 
Uric acid nephrolithiasis and metabolic syndrome: lack of ammonium  
 
 Urinary net acid excretion is the product of mechanisms acidifying urine such 
as Na+/H+-exchangers (mainly in the proximal tubule and the thick ascending limb of 
the loop of Henle) and H+-ATPases (along the proximal tubule, and mostly in the 
collecting duct system) and buffers that bind and neutralize protons such as citrate, 
phosphate, creatinine, and ammonia (7,19-20). Lower urinary concentrations of these 
buffers can cause more acidic urine which in turn can favor the crystallization of 
solutes such as cystine or uric acid. Patients with metabolic syndrome develop 
frequently uric acid kidney stones, which has been thought to be due to metabolic 
abnormalities increasing uric acid excretion. However, a more careful 
characterization of patients with metabolic syndrome or type II diabetes revealed an 
unique combination of normal urinary uric acid levels, rather acidic urine pH and low 
urinary ammonium levels suggesting that a lack of ammonia buffer may underlie the 
acidic urine and higher propensity to form uric acid crystals (21-23).  
 Urine ammonium concentrations are the result of renal ammoniagenesis and 
the subsequent transport of ammonium along the nephron and its subsequent 
secretion into urine at the level of the collecting duct (20,24). Ammoniagenesis 
occurs in the proximal tubule, requires glutamine as substrate, generates bicarbonate 
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and ammonia, and is closely linked to gluconeogenesis. Glutamine is taken up from 
blood via the SNAT3 amino acid transporter (25) and metabolized. This process is 
stimulated during acidosis and may also be regulated by insulin or glucocorticoids 
(25-28). Subsequently, ammonium is excreted mostly into urine by substituting for 
protons in the sodium/proton exchanger NHE3. Later, ammonium is partly 
reabsorbed in the thick ascending limb of the loop of Henle via the NKCC2 
cotransporter, accumulated in the interstitium and secreted as ammonia (NH3) into 
urine along the collecting duct. The last step, secretion of NH3 into urine is mediated 
by the RhCG rhesus protein, a novel NH3 transporting protein (19-20,29).  
Bobulescu and colleagues used obese and diabetic rats to further investigate 
the mechanisms underlying lower levels of ammonium in patients with metabolic 
syndrome. They showed accumulation of lipids in the proximal tubule, reduced 
expression of the Na+/H+- exchanger NHE3, and resistance of NHE3 to the 
stimulatory action of insulin or glucocorticoids (30). In a reverse experiment, Zucker 
diabetic fatty rats were treated with thiazolidinediones to reduce fat mass which 
normalized urinary acidification and ammonium excretion (31). Similarly, we used 
mice fed a high calorie diet to induce obesity and relative insulin resistance. These 
mice had normal urinary pH and ammonium excretion at baseline but were less able 
to adapt to an acid load with lower urinary ammonium excretion (Busque and 
Wagner, unpublished results). We found highly elevated expression of the glutamine 
transporter SNAT3, and the ammoniagenic enzyme phosphate-dependent 
glutaminase as well as of the gluconeogenic enzyme phosphoenol pyruvate carboxy 
kinase (PEPCK) in the proximal tubule. However, the activity of the NHE3 Na+/H+ 
exchanger in the brush border membrane of the proximal tubule was reduced. Taken 
together all data suggest that obesity and a state of relative or absolute insulin 
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resistance affect urinary ammonium excretion mostly at the level of the proximal 
tubule and that dysregulation of NHE3 may play an important role in reducing 
ammonium excretion. Expression of RhCG as final mediator of ammonia excretion 
remained normal in obese and insulin-resistant mice. 
 
Urinary calcium can stimulate urinary acidification 
 
Thus various defects in urinary acidification or deranged systemic acid-base 
status can affect the excretion and concentration of solutes in urine. Is there a 
feedback mechanism by which the concentration of urinary solutes can affect urinary 
pH by other means than changing simply buffering power ? Mice lacking the TRPV5 
calcium channel, the major reabsorptive pathway for transcellular calcium 
reabsorption in the late distal convoluted tubule and connecting tubule, excrete 
massive amounts of calcium in urine. Moreover, urinary phosphate excretion is also 
enhanced, possibly due to elevated vitamin D3 levels and stimulated intestinal 
phosphate absorption. However, these mice do not show signs of nephrocalcinosis or 
kidney stone formation (32). The massive increase in urinary calcium und phosphate 
excretion is paralleled by enhanced diuresis and also a very acidic urine, two factors, 
that may reduce the risk for the formation of calcium phosphate crystals. Sands and 
colleagues had shown that the collecting duct expresses luminal Calcium-sensing 
receptors (CaSR) (33) and that stimulation of the CaSR reduces basal and 
vasopressin stimulated water absorption via the AQP2 water channel. Consistently, 
mice lacking TRPV5 had reduced AQP2 water channel expression which may 
contribute to the higher diuresis. We also tested the hypothesis that high luminal 
calcium may stimulate urinary acidification by vacuolar type H+-ATPases expressed 
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in intercalated cells (34). The activity of these H+-ATPases is stimulated by a variety 
of hormones such as angiotensin II, aldosterone or endothelin or by increases in CO2 
or during metabolic acidosis (35-39). Isolated collecting ducts from wildtype and 
TRPV5 KO mice had similar H+-ATPase activity. However, high calcium or neomycin 
stimulated H+-ATPase activity suggesting that Calcium-sensing receptors or a related 
sensor may sense luminal calcium concentrations and regulate urinary acidification 
by stimulating H+-ATPase activity.  
 
Does increased urinary acidification by H+-ATPases protect from the formation 
of kidney stones in mice with hypercalcuria and hyperphosphaturia ? We tested this 
hypothesis by crossing TPRV5 KO mice with mice lacking the B1 H+-ATPase subunit. 
The B1 subunit forms part of the cytosolic H+-ATPase domain, is selectively 
expressed in intercalated cells, and is required for maximal urinary acidification 
(35,37,40-41). Patients with mutations in the B1 H+-ATPase gene ATP6V1B1 suffer 
from distal renal tubular acidosis with sensorineural deafness (42). B1 KO mice 
excrete a more alkaline urine than wildtype mice but do not develop kidney stones. 
Double KO mice (TRPV5-B1) excreted high amounts of calcium and phosphate but 
with a more alkaline urine than TRPV5 KO mice. These mice died a few weeks after 
birth with massive hydronephrosis and kidney stones. Detailed analysis of 
calcifications and stones demonstrated a composition mainly of phosphate and 
calcium. Thus, H+-ATPase mediated urinary acidification prevents the formation of 
calcium phosphate containing kidney stones in a mouse model of excessive 
hypercalciuria. 
It has been debated whether these protective mechanism can be translated 
from mouse to man (43). Major differences between hypercalciuric patients and the 
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TRPV5 KO mouse model may be the level of urinary calcium which is very highly 
elevated in these mice. Possibly, rather very high calcium concentrations are needed 
to elicit these protective mechanisms.  
 
Summary 
 
Systemic acid-base status and urine pH have profound effects on the kidneys 
ability to secrete or reabsorb metabolites and solutes that contribute to the risk of 
stone formation. The elucidation of molecular mechanisms of transport have provided 
valuable insights into physiologic processes. Very little is known how changes in 
systemic or local pH translate into changes in transport functions, whether transport 
moelcules and ion channels are intrinsically pH-sensitive as suggested for some or 
whether local or systemic pH sensors trigger regulatory cascades affecting renal 
function. Nevertheless, some of the mechanisms outlined above contribute to the risk 
of stone formation in patients but in a large number of patients additional 
mechanisms must contribute to pathology since many patients with so-called 
idiopathic hypercalcuria do not display obvious problems in local or systemic pH 
regulation. In the case of uric acid kidney stones, the discovery that urinary 
ammonium excretion is deranged and the localization of this defect to the proximal 
tubule in experimental animal models has deepened our understanding of this 
particular type of kidney stones. 
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